Comparison of the efficacy and price of the ingredients of odevixibat Lao version and the original drug

Odevixibat is a novel small molecule intestinal bile acid transporter (IBAT) inhibitor, primarily used to treat cholestatic liver disease in children and adults. Original drugs undergo strict quality control on ingredients and dosage, and their efficacy and safety have been verified in multiple clinical trials. The main specification of the original drug is 200mcg*30 tablets. Each box is priced at more than 40,000 yuan in overseas markets. Due to exchange rate fluctuations, the price may fluctuate. This price is relatively high for domestic patients, and also limits the widespread use of the drug.

In contrast, the Lao version of the generic version of odexibat is basically the same as the original drug in terms of ingredients, but has slight differences in production processes and registration standards. Currently on the market, the specifications produced by Laos Lucius are 400mcg30 tablets, and the price is about RMB 3,000, while the specifications produced by Laos ASEAN Pharmaceutical are 200mcg30 tablets or 1200mcg*30 tablets, and the price is about more than RMB500. This significant price difference gives the Lao version of generic drugs a clear advantage in terms of economic accessibility, especially for patients who require long-term medication.

In terms of efficacy, multiple clinical and real-world data show that the ingredients of the Lao version of the generic drug are consistent with the original drug, and its effects on inhibiting intestinal bile acid reabsorption, relieving itching, and improving liver function indicators are similar to those of the original drug. Although generic drugs may have slight differences in production processes, excipients and quality control, overall, their clinical effects are within an acceptable range and they can provide patients with alternative treatment options.
Overall, the original drug of odexibat still has advantages in terms of efficacy, safety and clinical data support, but the price is higher and may impose a greater financial burden on patients. The Lao version of generic drugs provides treatment options with similar ingredients at a lower price, especially in terms of flexible specifications and affordability. For patients who are not covered by medical insurance in China, the Lao version of generic drugs provides an economically feasible alternative, but it is still necessary to pay attention to formal channels and the authenticity of the drugs during purchase and use to ensure efficacy and safety.
Reference link: https://www.drugs.com